z-logo
open-access-imgOpen Access
United States oncologists’ clinical preferences regarding modes of medicinal cannabis use
Author(s) -
Sannes Timothy S.,
Nayak Manan M.,
Tung Stephanie,
Chai Peter R.,
Yusufov Miryam,
BolcicJankovic Dragana,
Pirl William F.,
Braun Ilana M.
Publication year - 2021
Publication title -
cancer communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.119
H-Index - 53
ISSN - 2523-3548
DOI - 10.1002/cac2.12160
Subject(s) - cannabis , medicine , psychiatry , psychology
Dear Editor, Almost every state in the United States with a comprehensive medicinal cannabis (MC) law identifies cancer as a qualifying condition for MC use [1, 2]. A growing body of scientific literature indicates that cancer patients use MC for both symptom management (e.g., pain, low appetite, fatigue,mood disturbance) and cancer-directed therapy [3, 4]. While survey research suggests that cannabis is most typically consumed via combustion, cannabis ismost often consumed orally among cancer patients [5]. Data from a nationally-representative sample of medical oncologists indicate that 80% of them discuss MC with patients and nearly half recommend cannabis clinically [6]. However, little is known about oncologists’ views on different modes of MC use. This study, a secondary analysis of the above-mentioned national survey [6], explored oncologists’ preferences regarding different modes (combustion, smoking, vaporization, and ingested) of MC use. We examined providerlevel and practice-level predictors of these preferences. We hypothesized that oncologists would favor oral MC use given similar trends among medical providers caring for patients with other serious illnesses [7] and potential stigma in the medical community regarding combustion. Between November 2016 and January 2017, a nationallyrepresentative sample of board-certified, medical oncologists was surveyed about their views on MC. The corresponding full methodological details are described elsewhere [6]. Briefly, the survey was mailed to a nationally-representative sample [6], MC was defined as non-pharmaceutical cannabis, and the item of interest was presented in a multiple-select response format: “What mode(s) of medical marijuana use do you prefer for your oncology patients?” (possible responses: “smoking,” “vaporizing,” “ingesting orally,” “no preference,” “I don’t know,” or “do not support medical marijuana”). To simplify interpretation, survey participants who “[did] not support medical marijuana use of any sort”

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here